AVI Antisense Drug Battles Bird Flu
Posted on: Friday, 27 October 2006, 15:01 CDT
U.S. firm AVI BioPharma says pre-clinical data show antisense drug Neugene beats multiple strains of Influenza A, including bird flu.
In the study, eight Neugene antisense drugs were evaluated for their ability to inhibit influenza A virus by blocking the complementary RNA sequences that are highly conserved across viral subtypes, the company said.
AVI said a number of the agents were highly efficacious, each reducing viral titer in a dose-responsive and sequence-specific manner. But of the eight Neugene agents tested, two worked especially well in subduing the influenza A virus, including strains H1N1, H3N2, H3N8, H7N7 and most importantly, the deadly H5N1 avian virus, or bird flu.
This latest publication is further evidence that Neugene drugs offer a broad-spectrum therapeutic approach to treating a high percentage of known influenza viral strains, said Patrick Iversen, senior vice president of research and development at AVI. Two of the Neugene drugs used in these studies have now moved into preclinical animal studies against both seasonal and avian influenza strains.
Source: United Press International
Related Articles
- Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013
- India's Hepatitis C Virus Drug Market Will Grow to More Than $171 Million By 2012
- China's Hepatitis C Virus Drug Market Will Grow to $150 Million By 2012
- China's Hepatitis B Virus Drug Market Will Grow to $800 Million By 2012
- India's Hepatitis B Virus Drug Market Will Grow Ten-Fold By 2012
- AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals
- AVI BioPharma Presents Successful Trial Results Using NEUGENE Antisense to Alter Drug Metabolism in Humans
- Alnylam and Collaborators Present Pre-Clinical Data for RNAi Therapeutics for the Treatment of Respiratory Diseases Including Pandemic Influenza; Results Include Data on Anti-Viral Activity of RNAi Therapeutics Toward H5N1 Virus
- AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza; NEUGENE Antisense Efficacy Against Influenza Strains Reported at the International Conference on Antiviral Research
- Vietnam to Upgrade Hospitals, Ensure Supply of Anti-Virus Drugs
 |
 |
User Comments (0)
RSS Feeds